ImmuPharma Calls General Meeting to Approve Fundraising Plans

ImmuPharma ( (GB:IMM) ) just unveiled an update.

ImmuPharma has published a shareholder circular and formally convened a General Meeting for 7 April 2026 in London, following its recent fundraising announcement. The circular, to be made available on the company’s website, sets out details requiring shareholder approval, underlining the importance of investor consent in progressing the company’s latest capital-raising plans and associated corporate actions.

The move signals a key governance step in ImmuPharma’s financing process, with the General Meeting providing a forum for shareholders to validate the terms of the fundraising. The outcome will influence the company’s balance sheet strength and its capacity to advance its development pipeline, making the meeting a notable event for investors and other stakeholders tracking its capital strategy.

The most recent analyst rating on (GB:IMM) stock is a Sell with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.

Spark’s Take on IMM Stock

According to Spark, TipRanks’ AI Analyst, IMM is a Neutral.

The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.

To see Spark’s full report on IMM stock, click here.

More about ImmuPharma

ImmuPharma PLC is a UK-based specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio targets autoimmune diseases and anti-infective indications, positioning the group within the innovative drug discovery segment of the life sciences sector.

Average Trading Volume: 3,612,064

Technical Sentiment Signal: Sell

Current Market Cap: £24.94M

See more data about IMM stock on TipRanks’ Stock Analysis page.